GBP13.77
0.36% yesterday
London, Aug 28, 05:36 pm CET
ISIN
GB0009223206
Symbol
SN

Smith & Nephew Stock price

GBP13.77
+2.06 17.59% 1M
+2.45 21.62% 6M
+4.01 41.14% YTD
+2.34 20.45% 1Y
+4.51 48.74% 3Y
+0.38 2.81% 5Y
+4.46 47.97% 10Y
+10.17 282.91% 20Y
London, Closing price Thu, Aug 28 2025
-0.05 0.36%

Key metrics

Basic
Market capitalization
GBP12.0b
Enterprise Value
GBP14.1b
Net debt
GBP2.1b
Cash
GBP500.4m
Shares outstanding
876.0m
Valuation (TTM | estimate)
P/E
33.6 | 17.0
P/S
2.7 | 2.6
EV/Sales
3.2 | 3.0
EV/FCF
23.9
P/B
2.9
Dividends
DPS
GBP0.29
Yield 1Y | 5Y
2.1% | 2.5%
Growth 1Y | 5Y
-5.9% | -0.9%
Payout 1Y | 3Y
81.7% | 118.8%
Increased
0 Years
Financials (TTM | estimate)
Revenue
GBP4.4b | GBP4.6b
EBITDA
GBP788.3m | GBP1.2b
EBIT
GBP659.5m | GBP805.3m
Net Income
GBP363.4m | GBP709.0m
Free Cash Flow
GBP589.9m
Growth (TTM | estimate)
Revenue
5.4% | 7.8%
EBITDA
19.9% | 45.3%
EBIT
28.0% | 22.3%
Net Income
61.0% | 132.5%
Free Cash Flow
164.8%
Margin (TTM | estimate)
Gross
70.0%
EBITDA
17.9% | 26.0%
EBIT
15.0%
Net
8.3% | 15.3%
Free Cash Flow
13.4%
Financial Health
Equity Ratio
50.9%
Return on Equity
7.8%
ROCE
9.7%
ROIC
8.4%
Debt/Equity
0.6
More
EPS
GBP0.4
FCF per Share
GBP0.7
Short interest
73.0%
Employees
17k
Rev per Employee
GBP250.0k
Show more

Is Smith & Nephew a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Smith & Nephew Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Smith & Nephew forecast:

13x Buy
52%
11x Hold
44%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Smith & Nephew forecast:

Buy
52%
Hold
44%
Sell
4%

Financial data from Smith & Nephew

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,400 4,400
5% 5%
100%
- Direct Costs 1,318 1,318
2% 2%
30%
3,081 3,081
7% 7%
70%
- Selling and Administrative Expenses 2,075 2,075
4% 4%
47%
- Research and Development Expense 218 218
5% 5%
5%
788 788
20% 20%
18%
- Depreciation and Amortization 129 129
9% 9%
3%
EBIT (Operating Income) EBIT 659 659
28% 28%
15%
Net Profit 363 363
61% 61%
8%

In millions GBP.

Don't miss a Thing! We will send you all news about Smith & Nephew directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Deepak Nath
Employees 17,349
Founded 1856
Website www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today